Brain Tumor News Blast!

This news brief is bought to you by:
The Musella Foundation For Brain Tumor Research & Information.

To unsubscribe, go to: http://virtualtrials.com/remove.cfm?r=fpac.rangola@blogger.com

To view past stories - or submit a story / press release, go to:
http://www.virtualtrials.com/news.cfm

=====================================================================
http://virtualtrials.com/news3.cfm?item=4427 :Celprogen Introduces an in vivo Model for Human Brain Cancer (Human Glioblastoma GBM) for Drug Discovery Applications

=====================================================================
http://virtualtrials.com/news3.cfm?item=4429 : Phase I/II Trial Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177.

=====================================================================
http://virtualtrials.com/news3.cfm?item=4430 : Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme.

=====================================================================
http://virtualtrials.com/news3.cfm?item=4431 : Pediatric glioblastomas: A histopathological and molecular genetic study.

=====================================================================
http://virtualtrials.com/news3.cfm?item=4432 :Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience.

=====================================================================
http://virtualtrials.com/news3.cfm?item=4428 : Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab (Avastin) plus irinotecan (CPT-11).

=====================================================================
http://virtualtrials.com/news3.cfm?item=4433 :abCorp developing new brain cancer test